Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Suppression of CML Progenitor but Not Stem Cells Requires Simultaneous Inhibition of KIT and BCR-ABL1.

Zhimin Gu, PhD, Amie S. Corbin, Thomas O'Hare, PhD, Anna M. Eiring, PhD, Tian yi Zhang, Brian J. Druker, Michael W. Deininger, MD, PhD

Blood (2012) 120 (21): 2778.

https://doi.org/10.1182/blood.V120.21.2778.2778

Published: 2012

Journal Articles

The BCR-ABL 35INS insertion/truncation mutant is kinase-inactive and does not contribute to tyrosine kinase inhibitor resistance in chronic myeloid leukemia

Thomas O'Hare, Matthew S. Zabriskie, Christopher A. Eide, Anupriya Agarwal, Lauren T. Adrian, Huihong You, Amie S. Corbin, Fei Yang, Richard D. Press, Victor M. Rivera, Julie Toplin, Stephane Wong, Michael W. Deininger, Brian J. Druker

Blood (2011) 118 (19): 5250–5254.

https://doi.org/10.1182/blood-2011-05-349191

Published: 2011

Includes: Supplemental data

Journal Articles

Suppression of CML Progenitor but Not CML Stem Cell Growth Requires Dual Inhibition of BCR-ABL and KIT

Amie S. Corbin, Thomas O’Hare, Brian J. Druker, Michael W.N. Deininger

Blood (2008) 112 (11): 190.

https://doi.org/10.1182/blood.V112.11.190.190

Published: 2008

Journal Articles

Absence of SKP2 expression attenuates BCR-ABL–induced myeloproliferative disease

Anupriya Agarwal, Thomas G. P. Bumm, Amie S. Corbin, Thomas O'Hare, Marc Loriaux, Jonathan VanDyke, Stephanie G. Willis, Jutta Deininger, Keiichi I. Nakayama, Brian J. Druker, Michael W. Deininger

Blood (2008) 112 (5): 1960–1970.

https://doi.org/10.1182/blood-2007-09-113860

Published: 2008

Includes: Supplemental data

Journal Articles

RNAi screening of the tyrosine kinome identifies therapeutic targets in acute myeloid leukemia

Jeffrey W. Tyner, Denise K. Walters, Stephanie G. Willis, Mary Luttropp, Jason Oost, Marc Loriaux, Heidi Erickson, Amie S. Corbin, Thomas O'Hare, Michael C. Heinrich, Michael W. Deininger, Brian J. Druker

Blood (2008) 111 (4): 2238–2245.

https://doi.org/10.1182/blood-2007-06-097253

Published: 2008

Includes: Supplemental data

Journal Articles

SGX70393 Inhibits Bcr-Abl T315I In Vitro and In Vivo and Completely Suppresses Resistance When Combined with Nilotinib or Dasatinib.

Thomas O’Hare, Christopher A. Eide, Jeffrey W. Tyner, Amie S. Corbin, Matthew J. Wong, Sean Buchanan, Kevin Holme, Katayoun A. Jessen, Crystal Tang, Hal A. Lewis, Richard D. Romero, Stephen K. Burley, Michael W. Deininger

Blood (2007) 110 (11): 535.

https://doi.org/10.1182/blood.V110.11.535.535

Published: 2007

Journal Articles

Potent Antitumor Activity of AP24534, an Orally Active Inhibitor of Bcr-Abl Variants Including T315I, in In Vitro and In Vivo Models of Chronic Myeloid Leukemia (CML).

Victor M. Rivera, PhD, Qihong Xu, PhD, Frank Wang, PhD, Joseph Snodgrass, PhD, Thomas O’Hare, PhD, Amie S. Corbin, Jeffrey Keats, Sarah Lamore, Yaoyu Ning, Scott Wardwell, Karin Russian, Marc Broudy, William C. Shakespeare, PhD, Brian J. Druker, MD, John D. Iuliucci, PhD, Tim Clackson, PhD

Blood (2007) 110 (11): 1032.

https://doi.org/10.1182/blood.V110.11.1032.1032

Published: 2007

Journal Articles

Inhibition of T315I Bcr-Abl and Other Imatinib-Resistant Bcr-Abl Mutants by the Selective Abl Kinase Inhibitor SGX70393.

Thomas O’Hare, PhD, Christopher A. Eide, Jeffrey W. Tyner, PhD, Matthew J. Wong, Caitlyn A. Smith, Amie S. Corbin, Sean Buchanan, PhD, Katayoun A. Jessen, PhD, Crystal Tang, Kevin Holme, PhD, Stephen K. Burley, MD, PhD, Michael W.N. Deininger, MD, PhD

Blood (2006) 108 (11): 1373.

https://doi.org/10.1182/blood.V108.11.1373.1373

Published: 2006

Journal Articles

Dasatinib (BMS-354825), a Multi-Targeted Kinase Inhibitor, Inhibits the Kinase Activity of Wild-Type, Juxtamembrane and Activation Loop Mutant Kit Isoforms Associated with Human Malignancies.

Marcus M. Schittenhelm, MD, Sharon Shiraga, Arin Schroeder, Amie S. Corbin, Diana Griffith, Francis Y. Lee, PhD, Michael W. Deininger, MD, PhD, Brian J. Druker, MD, Michael C. Heinrich, MD

Blood (2005) 106 (11): 3358.

https://doi.org/10.1182/blood.V106.11.3358.3358

Published: 2005

Journal Articles

A Gene Polymorphism within the Kinase Domain of BCR-ABL and Its Effects on Sensitivity to Tyrosine Kinase Inhibitors.

Lucy C. Crossman, MD, Thomas O’Hare, PhD, Thoralf Lange, MD, Stephanie G. Willis, Eric P. Stoffregen, Amie S. Corbin, Stephen G. O’Brien, MD, PhD, Michael C. Heinrich, MD, Brian J. Druker, MD, Peter G. Middleton, PhD, Michael W.N. Deininger, MD, PhD

Blood (2005) 106 (11): 1530.

https://doi.org/10.1182/blood.V106.11.1530.1530

Published: 2005

Journal Articles

In vitro and in vivo activity of ATP-based kinase inhibitors AP23464 and AP23848 against activation-loop mutants of Kit

Amie S. Corbin, Shadmehr Demehri, Ian J. Griswold, Yihan Wang, Chester A. Metcalf, III, Raji Sundaramoorthi, William C. Shakespeare, Joseph Snodgrass, Scott Wardwell, David Dalgarno, John Iuliucci, Tomi K. Sawyer, Michael C. Heinrich, Brian J. Druker, Michael W. N. Deininger

Blood (2005) 106 (1): 227–234.

https://doi.org/10.1182/blood-2004-12-4771

Published: 2005

Includes: Supplemental data

Journal Articles

Sensitivity of oncogenic KIT mutants to the kinase inhibitors MLN518 and PD180970

Amie S. Corbin, Ian J. Griswold, Paul La Rosée, Kevin W. H. Yee, Michael C. Heinrich, Corinne L. Reimer, Brian J. Druker, Michael W. N. Deininger

Blood (2004) 104 (12): 3754–3757.

https://doi.org/10.1182/blood-2004-06-2189

Published: 2004

Journal Articles

In Vitro and In Vivo Activity of the Src/Abl Kinase Inhibitor AP23464 and Analogs Against Activation Loop Mutants of KIT.

Amie S. Corbin, Shadmehr Demehri, Ian J. Griswold, Chester A. Metcalf, III, William C. Shakespeare, Joseph Snodgrass, Scott Wardwell, David C. Dalgarno, John Iuliucci, Tomi K. Sawyer, Brian J. Druker, Michael W. Deininger

Blood (2004) 104 (11): 793.

https://doi.org/10.1182/blood.V104.11.793.793

Published: 2004

Journal Articles

Murine Model of Aggressive Systemic Mastocytosis: A Disease Caused by Oncogenic Kit.

Shadmehr Demehri, Amie S. Corbin, Marc Loriaux, MD, Brian J. Druker, MD, Michael W. Deininger, MD, PhD

Blood (2004) 104 (11): 2426.

https://doi.org/10.1182/blood.V104.11.2426.2426

Published: 2004

Journal Articles

In vitro efficacy of combined treatment depends on the underlying mechanism of resistance in imatinib-resistant Bcr-Abl–positive cell lines

Paul La Rosée, Kara Johnson, Amie S. Corbin, Eric P. Stoffregen, Erika M. Moseson, Stephanie Willis, Michael M. Mauro, Junia V. Melo, Michael W. Deininger, Brian J. Druker

Blood (2004) 103 (1): 208–215.

https://doi.org/10.1182/blood-2003-04-1074

Published: 2004

Journal Articles

Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib

Amie S. Corbin, Paul La Rosée, Eric P. Stoffregen, Brian J. Druker, Michael W. Deininger

Blood (2003) 101 (11): 4611–4614.

https://doi.org/10.1182/blood-2002-12-3659

Published: 2003

NARROW

Suppression of CML Progenitor but Not Stem Cells Requires Simultaneous Inhibition of KIT and BCR-ABL1.

The BCR-ABL 35INS insertion/truncation mutant is kinase-inactive and does not contribute to tyrosine kinase inhibitor resistance in chronic myeloid leukemia

Suppression of CML Progenitor but Not CML Stem Cell Growth Requires Dual Inhibition of BCR-ABL and KIT

Absence of SKP2 expression attenuates BCR-ABL–induced myeloproliferative disease

RNAi screening of the tyrosine kinome identifies therapeutic targets in acute myeloid leukemia

SGX70393 Inhibits Bcr-Abl T315I In Vitro and In Vivo and Completely Suppresses Resistance When Combined with Nilotinib or Dasatinib.

Potent Antitumor Activity of AP24534, an Orally Active Inhibitor of Bcr-Abl Variants Including T315I, in In Vitro and In Vivo Models of Chronic Myeloid Leukemia (CML).

Inhibition of T315I Bcr-Abl and Other Imatinib-Resistant Bcr-Abl Mutants by the Selective Abl Kinase Inhibitor SGX70393.

Dasatinib (BMS-354825), a Multi-Targeted Kinase Inhibitor, Inhibits the Kinase Activity of Wild-Type, Juxtamembrane and Activation Loop Mutant Kit Isoforms Associated with Human Malignancies.

A Gene Polymorphism within the Kinase Domain of BCR-ABL and Its Effects on Sensitivity to Tyrosine Kinase Inhibitors.

In vitro and in vivo activity of ATP-based kinase inhibitors AP23464 and AP23848 against activation-loop mutants of Kit

Sensitivity of oncogenic KIT mutants to the kinase inhibitors MLN518 and PD180970

In Vitro and In Vivo Activity of the Src/Abl Kinase Inhibitor AP23464 and Analogs Against Activation Loop Mutants of KIT.

Murine Model of Aggressive Systemic Mastocytosis: A Disease Caused by Oncogenic Kit.

In vitro efficacy of combined treatment depends on the underlying mechanism of resistance in imatinib-resistant Bcr-Abl–positive cell lines

Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only